Precision BioSciences Inc (DTIL)vsEli Lilly and Company (LLY)
DTIL
Precision BioSciences Inc
$7.28
-3.77%
HEALTHCARE · Cap: $288.76M
LLY
Eli Lilly and Company
$1,433.55
-0.82%
HEALTHCARE · Cap: $1.27T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 191859% more annual revenue ($86.46B vs $45.04M). LLY leads profitability with a 31.9% profit margin vs -85.6%. DTIL trades at a lower P/E of 30.3x. LLY earns a higher WallStSmart Score of 74/100 (B).
DTIL
Avoid26
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+56.6%
Fair Value
$9.38
Current Price
$7.28
$2.10 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : DTIL
The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.35 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 26/100), backed by strong 31.9% margins and 38.6% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?